Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Update in inclusion body myositis.
[inclusion body myositis]
The
purpose
of
this
study
is
to
review
recent
scientific
advances
relating
to
the
natural
history
,
cause
,
treatment
and
serum
and
imaging
biomarkers
of
inclusion
body
myositis
(
IBM
)
.
Several
theories
regarding
the
aetiopathogenesis
of
IBM
are
being
explored
and
new
therapeutic
approaches
are
being
investigated
.
New
diagnostic
criteria
have
been
proposed
,
reflecting
the
knowledge
that
the
diagnostic
pathological
findings
may
be
absent
in
patients
with
clinically
typical
IBM
.
The
role
of
MRI
in
IBM
is
expanding
and
knowledge
about
pathological
biomarkers
is
increasing
.
The
recent
description
of
autoantibodies
to
cytosolic
5
'
nucleotidase
1
A
in
patients
with
IBM
is
a
potentially
important
advance
that
may
aid
early
diagnosis
and
provides
new
evidence
regarding
the
role
of
autoimmunity
in
IBM
.
IBM
remains
an
enigmatic
and
often
misdiagnosed
disease
.
The
pathogenesis
of
the
disease
is
still
not
fully
understood
.
To
date
,
pharmacological
treatment
trials
have
failed
to
show
clear
efficacy
.
Future
research
should
continue
to
focus
on
improving
understanding
of
the
pathophysiological
mechanisms
of
the
disease
and
on
the
identification
of
reliable
and
sensitive
outcome
measures
for
clinical
trials
.
IBM
is
a
rare
disease
and
international
multicentre
collaboration
for
trials
is
important
to
translate
research
advances
into
improved
patient
outcomes
.
Diseases
Validation
Diseases presenting
"provides new evidence regarding the role of autoimmunity in ibm"
symptom
inclusion body myositis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom